Texas fees apply only to in-state device firms starting in 1996; all U.S. firms owe this year.
This article was originally published in The Gray Sheet
Executive Summary
TEXAS ANNUAL LICENSING FEES FOR IN-STATE DEVICE COMPANIES ONLY will be required beginning Jan. 1, 1996, according to staffers at the Texas Department of Health (TDH). A measure passed May 27 by the Texas state legislature repeals licensing fees on non-Texan U.S. device companies that ship products into the state, but continues to require payment from Texan device manufacturers and distributors. The amendment will take effect on Sept. 1.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.